Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690347 | 0.92 | PKM (0.41) | FFAR1FFAR4PKMNPC1RAB9A | |
| SCHEMBL16690405 | 0.89 | PKM (0.43) | PKMNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16690380 | 0.87 | MRGPRX4 (0.42) | FFAR1FFAR4PKMNPC1RAB9A | |
| SCHEMBL16690429 | 0.86 | MAOB (0.45) | FFAR4MAOAMAOB | |
| SCHEMBL16690382 | 0.83 | FFAR1 (0.37) | FFAR1FAAHP2RX3 | |
| SCHEMBL16690344 | 0.83 | PKM (0.39) | PKMNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16690349 | 0.81 | NPC1 (0.39) | PKMNPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16683840 | 0.81 | LMNA (0.41) | SMN1; SMN2 | |
| SCHEMBL16690383 | 0.80 | NOTUM (0.38) | MAOB | |
| SCHEMBL18037164 | 0.79 | MAOB (0.40) | PKMNPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015064727-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | TCOF1, TAOK2, CYC1 | FFAR1 919/4885FFAR4 2970/4885ALKBH1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.